4 min.
It was already clear that the BRAF/MEK-combination cobimetinib + vemurafenib performs better then vemurafenib + placebo in terms of efficacy. On the SMR 2019 five-year survival results were presented. Prof. Grant McArthur talks you through the efficacy and toxicity and discusses the significance of these new data on daily clinical practice.